Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cytokinetics (CYTK)
J.P. Morgan analyst Tessa Romero maintained a Buy rating on Cytokinetics today. The company’s shares closed last Tuesday at $70.10, close to its 52-week high of $75.71.
According to TipRanks.com, Romero is a 4-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $92.79, which is a 35.6% upside from current levels. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.
See today’s best-performing stocks on TipRanks >>
Regeneron (REGN)
Citi analyst Geoff Meacham reiterated a Buy rating on Regeneron today and set a price target of $900.00. The company’s shares closed last Tuesday at $772.19.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $872.23 average price target, an 11.8% upside from current levels. In a report issued on February 17, Canaccord Genuity also maintained a Buy rating on the stock with a $1057.00 price target.
